Through the SHH signaling system, combination therapy with sulforaphane and gefitinib dose-dependently decreases the growth of gefitinib-resistant lung cancer cells and inhibits the expression of SHH, SMO, and GLI1 [284]. Here, SHH is linked to lung carcinoma.